Akonni Biosystems Awarded $435K National Institutes of Health (NIH) Grant to Develop Low Cost Point-of-Care Diagnostics for Mycobacterium tuberculosis Drug-Resistant Strains

FREDERICK, Md.--(BUSINESS WIRE)--Akonni Biosystems®, a molecular diagnostics (MDx) company focused on developing and manufacturing rapid, high multiplex solutions for infectious disease testing, today announced receipt of a $435K grant from the National Institutes of Biomedical Imaging and Bioengineering at the National Institutes of Health. The award will enable Akonni to accelerate development of its hands-free, sample-to-answer system for identifying a broader range of multi-drug resistant strains of Mycobacterium tuberculosis (MTB).
MORE ON THIS TOPIC